Instructions for Lasolvan (Ambroxol) 100 ml for inhalation
English product name
Lasolvan®
Release form:
p-r d/ingestion and ingal. 7.5 mg/1 ml: fl 100 ml with drip, combined with measuring cup
Description:
The solution for ingestion and inhalation is transparent, colorless or lightly browned.
1 ml
Ambroxol hydrochloride: 7.5 mg
Auxiliary substances:
citric acid monohydrate - 2 mg, sodium hydrophosphate dihydrate - 4.35 mg, sodium chloride - 6.22 mg, benzalkonium chloride - 225 mg, water purified - 989.705 mg.
100 ml bottles of amber glass (1) with a polyethylene drip and a polypropylene screw cap with the control of the first opening complete with a measuring cup - cardboard packs.
ATC codes
R05CB06 Ambroxol
Clinical-pharmacological groups / Group affiliation
Mucolytic and expectorant preparation
Active substance
Ambroxol hydrochloride
Pharmacotherapy group
Expectorant mucolytic agent
Storage Conditions
The drug should be stored in the original packaging in a place not accessible to children at a temperature not higher than 25 ° C.
Best before date
Shelf life is 5 years.
Testimony:
Acute and chronic respiratory diseases accompanied by the release of viscous sputum and disruption of mucociliary clearance:
acute and chronic bronchitis;
pneumonia;
COPD;
Bronchial asthma with difficulty of sputum withdrawal;
bronchiectasis.
How to take the medicine:
Ingestion (one ml = 25 drops).
Drops can be diluted in water, tea, juice or milk. The solution can be applied independently of the intake of food.
Adults and children over 12 years - four ml (100 drops) 3 times/day; children aged six to twelve - two ml (50 drops) 2-3 times/day; Children aged two to 6 years - one ml (25 drops) three times/day; Children under two years old - one ml (25 drops) twice per day.
Inhalations Ambroxol
Adults and children over 6 years old - one - two inhalations of two - three ml solution / day.
Children under six years old - one - two inhalations of two ml solution / day.
Lazolvan® inhalation solution can be used using any modern inhalation equipment (except steam inhalers). In order to achieve optimum hydration during inhalation, the preparation is mixed with a 0.9% sodium chloride solution in a ratio of 1:1. Because inhalation therapy can cause a cough, inhalation should be done in normal breathing. It is usually recommended to preheat the inhalation solution to body temperature before inhalation. Patients with bronchial asthma are advised to inhale after taking broncholytic drugs to avoid non-specific irritation of the airways and their spasm.
Drugs Ambroxol
Studies have shown that Ambroxol - the active ingredient of the drug Lasolvan® - increases secretion in the respiratory tract. Enhances the production of pulmonary surfactant and stimulates ciliary activity. These effects lead to increased current and mucus transport (mucociliary clearance). Increased mucociliary clearance improves the discharge of sputum and facilitates coughing.
